bioRxivBiochemistry
Development of LRRK2 designed ankyrin-repeat proteins
V. Dederer, M. Sanz Murillo, E. P. Karasmanis, K. S. Hatch, D. Chatterjee, F. Preuss, K. R. Abdul Azeez, L. V. Nguyen, C. Galicia, B. Dreier, A. Pluckthun, W. Versees, S. Mathea, A. E. Leschziner, S. L. Reck-Peterson, S. Knapp
Abstract
Leucine rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinsons disease (PD) has led to intense interest in determining its cellular function. However, small molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase.
- organism: human
- assay: proteomics
- research focus: protein folding & dynamics
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules
D. M. Snead, M. Matyszewski, … S. L. Reck-Peterson·bioRxiv·Jan 21, 2022
- Parkinson's Disease-linked LRRK2 structure and model for microtubule interaction
C. K. Deniston, J. Salogiannis, … A. E. Leschziner·bioRxiv·Jan 6, 2020
- Inhibition of Parkinsons Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures
A. E. Leschziner, M. Sanz Murillo, … S. Mathea·bioRxiv·Sep 7, 2023
- Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2
S. H. Schmidt, J.-H. Weng, … S. S. Taylor·bioRxiv·Jul 13, 2020
- Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2
R. K. Singh, A. Soliman, … W. Versees·bioRxiv·Aug 30, 2021
- Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2
Nicolai D. Raig, Katherine J. Surridge, … Stefan Knapp·Science AdvancesPeer-reviewed·Jun 6, 2025